JP7240097B2 - 屈折異常に対する素因を予測するための方法および試薬 - Google Patents
屈折異常に対する素因を予測するための方法および試薬 Download PDFInfo
- Publication number
- JP7240097B2 JP7240097B2 JP2017545686A JP2017545686A JP7240097B2 JP 7240097 B2 JP7240097 B2 JP 7240097B2 JP 2017545686 A JP2017545686 A JP 2017545686A JP 2017545686 A JP2017545686 A JP 2017545686A JP 7240097 B2 JP7240097 B2 JP 7240097B2
- Authority
- JP
- Japan
- Prior art keywords
- exon
- opsin gene
- opsin
- mrna
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 62
- 208000014733 refractive error Diseases 0.000 title claims description 47
- 239000003153 chemical reaction reagent Substances 0.000 title description 2
- 108050001704 Opsin Proteins 0.000 claims description 165
- 108020004999 messenger RNA Proteins 0.000 claims description 130
- 230000003321 amplification Effects 0.000 claims description 54
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 54
- 239000002299 complementary DNA Substances 0.000 claims description 43
- 239000002773 nucleotide Substances 0.000 claims description 35
- 102000010175 Opsin Human genes 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 230000000295 complement effect Effects 0.000 claims description 26
- 230000002441 reversible effect Effects 0.000 claims description 24
- 208000001491 myopia Diseases 0.000 claims description 21
- 230000004379 myopia Effects 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 18
- 239000000523 sample Substances 0.000 claims description 16
- 101000598988 Mus musculus Medium-wave-sensitive opsin 1 Proteins 0.000 claims description 15
- 102000054767 gene variant Human genes 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009396 hybridization Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 208000009278 Blue cone monochromatism Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 201000007728 blue cone monochromacy Diseases 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 230000004402 high myopia Effects 0.000 claims description 3
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 description 28
- 230000035772 mutation Effects 0.000 description 26
- 108700024394 Exon Proteins 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 20
- 102000054766 genetic haplotypes Human genes 0.000 description 19
- 101001137074 Homo sapiens Long-wave-sensitive opsin 1 Proteins 0.000 description 17
- 102100035576 Long-wave-sensitive opsin 1 Human genes 0.000 description 17
- 230000007547 defect Effects 0.000 description 16
- 101000598987 Homo sapiens Medium-wave-sensitive opsin 1 Proteins 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 108010003730 Cone Opsins Proteins 0.000 description 11
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 11
- 208000006992 Color Vision Defects Diseases 0.000 description 10
- 238000002571 electroretinography Methods 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 230000004438 eyesight Effects 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000004456 color vision Effects 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 108091008695 photoreceptors Proteins 0.000 description 6
- 102100037812 Medium-wave-sensitive opsin 1 Human genes 0.000 description 5
- 210000001766 X chromosome Anatomy 0.000 description 5
- 230000001594 aberrant effect Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 201000007254 color blindness Diseases 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- 201000000757 red-green color blindness Diseases 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000004393 visual impairment Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 101710106192 Short-wave-sensitive opsin 1 Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 206010047571 Visual impairment Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000003500 gene array Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000004853 protein function Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 208000029257 vision disease Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 206010020675 Hypermetropia Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101150040964 OPN1LW gene Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 102000004330 Rhodopsin Human genes 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 201000009310 astigmatism Diseases 0.000 description 2
- 230000000453 cell autonomous effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 201000006318 hyperopia Diseases 0.000 description 2
- 230000004305 hyperopia Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000010041 presbyopia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 102200141512 rs104893768 Human genes 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 208000036443 AIPL1-related retinopathy Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000036693 Color-vision disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 101150114678 OPN1MW gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000017794 Perilipin-2 Human genes 0.000 description 1
- 108010067163 Perilipin-2 Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 201000000761 achromatopsia Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000008615 cone dystrophy Diseases 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126284P | 2015-02-27 | 2015-02-27 | |
| US62/126,284 | 2015-02-27 | ||
| PCT/US2016/020033 WO2016138512A1 (en) | 2015-02-27 | 2016-02-29 | Methods and reagents for predicting predisposition to refractive error |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512121A JP2018512121A (ja) | 2018-05-17 |
| JP2018512121A5 JP2018512121A5 (enExample) | 2020-02-27 |
| JP7240097B2 true JP7240097B2 (ja) | 2023-03-15 |
Family
ID=56789879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545686A Active JP7240097B2 (ja) | 2015-02-27 | 2016-02-29 | 屈折異常に対する素因を予測するための方法および試薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10787707B2 (enExample) |
| EP (1) | EP3261525B1 (enExample) |
| JP (1) | JP7240097B2 (enExample) |
| KR (1) | KR102551638B1 (enExample) |
| CN (1) | CN107529987B (enExample) |
| AU (1) | AU2016225033B2 (enExample) |
| CA (1) | CA2977808A1 (enExample) |
| SG (2) | SG11201706933TA (enExample) |
| WO (1) | WO2016138512A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017306044B2 (en) | 2016-08-01 | 2022-07-14 | University Of Washington | Ophthalmic lenses for treating myopia |
| JP7222981B2 (ja) | 2017-05-08 | 2023-02-15 | サイトグラス・ヴィジョン・インコーポレイテッド | 近視を軽減するためのコンタクトレンズおよびその製造方法 |
| US10884264B2 (en) | 2018-01-30 | 2021-01-05 | Sightglass Vision, Inc. | Ophthalmic lenses with light scattering for treating myopia |
| AU2019302757B2 (en) | 2018-07-12 | 2022-09-01 | Sightglass Vision, Inc. | Methods and devices for reducing myopia in children |
| US12416818B2 (en) | 2019-03-01 | 2025-09-16 | Sightglass Vision, Inc. | Ophthalmic lenses for reducing myopic progression and methods of making the same |
| CA3137950A1 (en) | 2019-04-23 | 2020-10-29 | Sightglass Vision, Inc. | Ophthalmic lenses with dynamic optical properties for reducing development of myopia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009502119A (ja) | 2005-06-23 | 2009-01-29 | ユニヴェルスィタ’デッリ ストゥディ ディ ローマ ”トル ヴェルガータ” | Ｌｏｘ−１タンパク質をコードする遺伝子の選択的スプライシングアイソフォーム、及びその使用 |
| WO2012116248A1 (en) | 2011-02-24 | 2012-08-30 | Massachusetts Institute Of Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
| JP2014504873A (ja) | 2011-01-14 | 2014-02-27 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション | 眼軸長関連障害を診断および治療する方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US6706867B1 (en) | 2000-12-19 | 2004-03-16 | The United States Of America As Represented By The Department Of Health And Human Services | DNA array sequence selection |
| EP1256632A3 (en) | 2001-05-07 | 2004-01-02 | Smithkline Beecham Corporation | High throughput polymorphism screening |
| US20040110179A1 (en) | 2002-03-15 | 2004-06-10 | Shuber Anthony P. | Method for alteration detection |
| DE60300792T2 (de) | 2002-05-09 | 2005-12-01 | Matsushita Electric Industrial Co., Ltd., Kadoma | Inline-Elektronenkanone und Farbbildröhre mit selbiger |
| US20050208555A1 (en) | 2004-03-16 | 2005-09-22 | Affymetrix, Inc. | Methods of genotyping |
| US7906289B2 (en) | 2008-07-28 | 2011-03-15 | Kaohsiung Medical University | Using genetic polymorphisms of the BICD1 gene as a method for diagnosing and treating myopia |
| WO2010075319A2 (en) | 2008-12-22 | 2010-07-01 | The Medical College Of Wisconsin, Inc. | Method and apparatus for limiting growth of eye length |
| US20120172419A1 (en) * | 2009-09-15 | 2012-07-05 | Medical College Of Wisconsin Research Foundation Inc. | Reagents and methods for modulating cone photoreceptor activity |
| JP5901046B2 (ja) | 2010-02-19 | 2016-04-06 | 国立大学法人 千葉大学 | ＯＡＴＰ１Ｂ３ｍＲＮＡの新規な選択的スプライシングバリアント |
-
2016
- 2016-02-29 CN CN201680016871.XA patent/CN107529987B/zh active Active
- 2016-02-29 JP JP2017545686A patent/JP7240097B2/ja active Active
- 2016-02-29 WO PCT/US2016/020033 patent/WO2016138512A1/en not_active Ceased
- 2016-02-29 EP EP16756539.9A patent/EP3261525B1/en active Active
- 2016-02-29 SG SG11201706933TA patent/SG11201706933TA/en unknown
- 2016-02-29 AU AU2016225033A patent/AU2016225033B2/en not_active Ceased
- 2016-02-29 CA CA2977808A patent/CA2977808A1/en active Pending
- 2016-02-29 SG SG10202102575SA patent/SG10202102575SA/en unknown
- 2016-02-29 US US15/553,418 patent/US10787707B2/en active Active
- 2016-02-29 KR KR1020177025942A patent/KR102551638B1/ko active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009502119A (ja) | 2005-06-23 | 2009-01-29 | ユニヴェルスィタ’デッリ ストゥディ ディ ローマ ”トル ヴェルガータ” | Ｌｏｘ−１タンパク質をコードする遺伝子の選択的スプライシングアイソフォーム、及びその使用 |
| JP2014504873A (ja) | 2011-01-14 | 2014-02-27 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション | 眼軸長関連障害を診断および治療する方法 |
| WO2012116248A1 (en) | 2011-02-24 | 2012-08-30 | Massachusetts Institute Of Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
Non-Patent Citations (4)
| Title |
|---|
| Ｂｉｏｃｈｅｍ．Ｂｉｏｐｈｙｓ．Ｒｅｓ．Ｃｏｍｍｕｎ．（２０１２）Ｖｏｌ．４２４，Ｎｏ．１，ｐ．１５２－１５７ |
| Ｈｕｍ．Ｍｕｔａｔ．（２０１４）Ｖｏｌ．３５，Ｎｏ．１１，ｐ．１３５４－１３６２ |
| Ｈｕｍａｎ ＤＮＡ ｓｅｑｕｅｎｃｅ ｆｒｏｍ ｃｌｏｎｅ ＸＸ－ＱＣ８Ｂ６ ｏｎ ｃｈｒｏｍｏｓｏｍｅ Ｘ Ｃｏｎｔａｉｎｓ ｔｈｅ ＯＰＮ１ＬＷ ｇｅｎｅ ｆｏｒ ｏｐｓｉｎ １ （ｃｏｎｅ ｐｉｇｍｅｎｔｓ）， ｌｏｎｇ－ｗａｖｅ－ｓｅｎｓｉｔｉｖｅ （ｃｏｌｏｒ ｂｌｉｎｄｎｅｓｓ， ｐｒｏｔａｎ） ａｎｄ ｔｈｅ ３’ ｅｎｄ ｏｆ ｔｈｅ ＣＸｏｒｆ２Ｂ ｇｅｎｅ ｆｏｒ ｃｈｒｏｍｏｓｏｍｅ Ｘ ｏｐｅｎ ｒｅａｄｉｎｇ ｆｒａｍｅ ２Ｂ， ｃｏｍｐｌｅｔｅ ｓｅｑｕｅｎｃｅ，［ｏｎｌｉｎｅ］，ＧｅｎＢａｎｋ，２００９年１月１５日，Ａｃｃｅｓｓｉｏｎ Ｎｏ： Ｚ６８１９３，［検索日］令和４年５月１７日，ＵＲＬ，ｈｔｔｐｓ：／／ｗｗｗ．ｎｃｂｉ．ｎｌｍ．ｎｉｈ．ｇｏｖ／ｎｕｃｃｏｒｅ／１１２２２８３？ｓａｔ＝１８＆ｓａｔｋｅｙ＝２８４２０８９７ |
| Ｉｎｖｅｓｔ．Ｏｐｈｔｈａｌｍｏｌ．Ｖｉｓ．Ｓｃｉ．（２０１３）Ｖｏｌ．５４，Ｎｏ．２，ｐ．１３６１－１３６９ |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018512121A (ja) | 2018-05-17 |
| SG10202102575SA (en) | 2021-04-29 |
| US20180112268A1 (en) | 2018-04-26 |
| EP3261525A4 (en) | 2018-07-18 |
| EP3261525B1 (en) | 2021-09-29 |
| WO2016138512A1 (en) | 2016-09-01 |
| CN107529987A (zh) | 2018-01-02 |
| AU2016225033A1 (en) | 2017-10-12 |
| EP3261525A1 (en) | 2018-01-03 |
| KR20170122212A (ko) | 2017-11-03 |
| US10787707B2 (en) | 2020-09-29 |
| AU2016225033B2 (en) | 2021-11-11 |
| HK1248498A1 (zh) | 2018-10-19 |
| SG11201706933TA (en) | 2017-09-28 |
| CA2977808A1 (en) | 2016-09-01 |
| CN107529987B (zh) | 2021-04-20 |
| KR102551638B1 (ko) | 2023-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7240097B2 (ja) | 屈折異常に対する素因を予測するための方法および試薬 | |
| Hansen et al. | Genetic heterogeneity in microcornea-cataract: five novel mutations in CRYAA, CRYGD, and GJA8 | |
| Xu et al. | Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population | |
| Willoughby et al. | Defining the pathogenicity of optineurin in juvenile open-angle glaucoma | |
| Han et al. | Association of PAX6 polymorphisms with high myopia in Han Chinese nuclear families | |
| Annamaneni et al. | Association of vitamin D receptor gene start codon (Fok1) polymorphism with high myopia | |
| WO2005090602A2 (en) | Method for diagnosing or predicting susceptibility to optic nueropathy | |
| CN106282197B (zh) | 一种遗传性视网膜色素变性疾病的致病突变及其检测试剂 | |
| Zhang et al. | Mutational screening of 10 genes in Chinese patients with microphthalmia and/or coloboma | |
| EP1606418B1 (en) | Methods for the diagnosis and treatment of epilepsy | |
| Wang et al. | ABCA4 deep intronic variants contributed to nearly half of unsolved Stargardt cases with a milder phenotype | |
| Kelberman et al. | CYP1B1-Related anterior segment developmental anomalies: novel mutations for infantile glaucoma and Von Hippel's ulcer revisited | |
| CN107312859A (zh) | Aqp5基因在制备检测先天性白内障制品中的应用 | |
| HK1248498B (en) | Methods and reagents for predicting predisposition to refractive error | |
| CN115851918B (zh) | 一种导致视网膜营养不良的致病基因cfap410突变位点的应用及检测试剂 | |
| CN103820548B (zh) | Myo18a基因在制备先天性小眼球诊断制品中的应用 | |
| JP6998476B2 (ja) | 近視の発症リスクを判定する方法 | |
| US20070117095A1 (en) | Diagnostic method for neonatal or infantile epilepsy syndromes | |
| Acton | Open-Angle Glaucoma: New Insights for the Healthcare Professional: 2011 Edition: ScholarlyPaper | |
| Tonska | Agnieszka Piotrowska-Nowak, Ewa Kosior-Jarecka b, Aleksandra Schab, Dominika Wrobel-Dudzinska b, Ewa Bartnik, Tomasz Zarnowski b, Katarzyna Tonska | |
| CN115851898A (zh) | 一种bpes综合征致病基因foxl2突变位点的应用及其诊断试剂 | |
| KR100443503B1 (ko) | 가족성 고콜레스테롤혈증을 유발하는 인간 저밀도 지단백질 수용체 유전자의 돌연변이체, 이의 검출 방법 및 이 방법에 유용한 프라이머 | |
| CN117821580A (zh) | Fktn基因突变体、突变体蛋白、试剂、试剂盒及应用 | |
| den Hollander PhD | 4.5. Variants in the PRPF8 gene are associated with glaucoma. | |
| WO2011042295A1 (en) | Method for the diagnosis of limbal stem cell deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170825 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190121 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191004 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191016 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20200116 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200701 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201030 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201030 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20201110 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201214 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201215 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20210212 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20210216 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210702 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220118 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220407 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20220601 |
|
| C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20220601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220826 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230105 |
|
| C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20230111 |
|
| C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20230203 |
|
| C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20230203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230303 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7240097 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |